Bookmark and Share

Compound Summary for: CID 6445226

dabigatran etexilate

Also known as: Pradax; BIBR 1048; Pradaxa; Rendix; 211915-06-9; UNII-2E18WX195X; BIBR1048; S2132_Selleck; Pradaxa, Pradax, Prazaxa
Molecular Formula: C34H41N7O5   Molecular Weight: 627.73324   InChIKey: KSGXQBZTULBEEQ-UHFFFAOYSA-N
Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.    From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Literature
Patents
Biomolecular Interactions and Pathways
Classification
Chemical and Physical Properties
_ _